Octagon Capital Advisors LP: TAYSHA GENE THERAPIES INC (TSHA): Quarterly 13F Position History
As of Q1 2026, Octagon Capital Advisors LP reported 8,859,911 shares of TAYSHA GENE THERAPIES INC (TSHA), worth $39.6M and representing 4.4% of its 13F equity book. The position first appeared in Q4 2020 and has been disclosed across 22 13F-HR filings in Pactolio's tracked window.
- 8,859,911Shares Held (Latest Filing)
- $39.6MReported Market Value (Latest Filing)
- 4.4%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$9.1MQuarter-over-Quarter Value Change
- 12,592,500Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 22 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 8,859,911 | 0 | — | $39.6M | 4.4% | $4.5 |
| Q4 2025 | 8,859,911 | 207,589 | -2.3% | $48.7M | 6.1% | $5.5 |
| Q3 2025 | 9,067,500 | 3,525,000 | -28.0% | $29.7M | 4.6% | $3.3 |
| Q2 2025 | 12,592,500 | +10,167,500 | +419.3% | $29.1M | 6.4% | $2.3 |
| Q1 2025 | 2,425,000 | 8,025,000 | -76.8% | $17.8M | 3.5% | $7.3 |
| Q4 2024 | 10,450,000 | +5,877,778 | +128.6% | $18.1M | 3.1% | $1.7 |
| Q3 2024 | 4,572,222 | 0 | — | $9.2M | 1.5% | $2.0 |
| Q2 2024 | 4,572,222 | +1,542,222 | +50.9% | $10.2M | 1.7% | $2.2 |
| Q1 2024 | 3,030,000 | +3,030,000 | — | $8.7M | 1.1% | $2.9 |
| Q4 2023 | 0 | 2,777,778 | -100.0% | $0 | 0.0% | — |
| Q3 2023 | 2,777,778 | +2,777,778 | — | $8.8M | 1.5% | $3.2 |
| Q2 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2021 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2021 | 0 | 320,440 | -100.0% | $0 | 0.0% | — |
| Q2 2021 | 320,440 | 0 | — | $6.8M | 1.4% | $21.2 |
| Q1 2021 | 320,440 | 0 | — | $6.5M | 2.5% | $20.3 |
| Q4 2020 | 320,440 | — | — | $8.5M | 2.9% | $26.5 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Octagon Capital Advisors LP first disclose a TSHA position in 13F-HR filings?
Octagon Capital Advisors LP first reported TAYSHA GENE THERAPIES INC (TSHA) on its 13F-HR filing for the period ending 2020-12-31 (Q4 2020). The position has appeared on 22 reported quarters within Pactolio's tracked window.
What was Octagon Capital Advisors LP's most recent quarter-over-quarter share-count change in TSHA?
Octagon Capital Advisors LP held the same 8,859,911 shares of TSHA between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Octagon Capital Advisors LP's cost basis in TSHA?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.